Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Merck/Roche Co-Promote Pact Attempts To Shut Vertex Out Of HCV Protease Inhibitor Space

This article was originally published in The Pink Sheet Daily

Executive Summary

Roche will co-promote Merck's Victrelis with its own HCV drugs Pegasys and Copegus in the U.S.
Advertisement

Related Content

How Far Can Big Pharma Collaboration Go? Much Further, Executives Say
Biopharma In 2011: A Year Of Transition
J&J vs. Merck: The Race Is On As Incivek Passes First EU Regulatory Hurdle
Hepatitis C Marketing: Applying Primary Care Tactics To Specialty Products
Telaprevir Labeling Advantages Should Offset Higher Price In Hepatitis C Battle
Vertex's Next Steps Closely Watched Following Merck-Roche Deal On Victrelis
Vertex Prices Telaprevir At $49,200 For Course Of Therapy
Will World's Largest HCV Population Have Access To Newest Treatments?
Merck To Ship Hepatitis C Drug Victrelis To Pharmacies Within A Week
Merck To Ship Hepatitis C Drug Victrelis To Pharmacies Within A Week

Topics

Advertisement
UsernamePublicRestriction

Register

PS072248

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel